Table 5.
In vivo pharmacodynamic parameters of oxacillin products by multiple nonlinear regression (M-NLR).
| OXACILLIN (OXA) PRODUCTS | N | SEM | ED50 (mg/kg) | SEM | BD (mg/kg) | SEM | 1LKD (mg/kg) | SEM |
|---|---|---|---|---|---|---|---|---|
| Experiment 1 | ||||||||
| OXA-BMS (innovator) | 1.73 | 0.30 | 45.13 | 5.47 | 77.73 | 0.20 | 104.79 | 24.18 |
| OXA-OPH | 0.47 | 0.09 | 95.15 | 35.54 | >750.00 | - | >750.00 | - |
| OXA-MEM | 0.56 | 0.10 | 76.42 | 24.90 | 409.36 | 182.35 | >750.00 | - |
| OXA-SCA | 0.56 | 0.10 | 72.66 | 23.71 | 390.13 | 172.68 | >750.00 | - |
| OXA-VIT | 0.45 | 0.10 | 205.11 | 84.98 | 750.00* | 373.73 | >750.00 | - |
| Experiment 2 | ||||||||
| OXA-BMS (innovator) | 1.73 | 0.18 | 45.13 | 3.33 | 60.71 | 4.33 | 96.48 | 12.24 |
| OXA-CAR | 0.64 | 0.07 | 90.52 | 16.50 | 202.51 | 39.36 | 230.84 | 230.84 |
| Experiment 3 | ||||||||
| OXA-BMS (innovator) | 1.73 | 0.29 | 45.13 | 5.39 | 62.17 | 7.07 | 97.35 | 20.07 |
| OXA-MEM | 0.63 | 0.12 | 127.53 | 38.29 | 307.47 | 101.82 | >750.00 | - |
| OXA-OPH | 0.55 | 0.10 | 128.00 | 42.18 | 526.98 | 225.98 | >750.00 | - |
| OXA-BLA | 0.59 | 0.11 | 101.00 | 31.58 | 259.22 | 88.45 | >750.00 | - |
| Experiment 4 | ||||||||
| OXA-BMS (innovator) | 1.73 | 0.21 | 45.13 | 3.96 | 49.23 | 3.83 | 88.41 | 17.53 |
| OXA-QUIM | 0.40 | 0.08 | 750.00 | 321.55 | 750.00* | 287.80 | 750.00* | 327.88 |
| OXA-COL | 0.58 | 0.09 | 221.34 | 54.59 | 287.58 | 70.52 | 750.00* | 356.95 |
Under this analysis, maximum effect (Emax) for all products is fixed to the innovator's (Emax= 5.42 log10 CFU/g).
Abbreviators: N: Hill's slope; ED50: effective dose to reach 50% of Emax; BD: bacteriostatic dose; 1LKD: 1 log kill dose; SEM: standard error of the mean; Bold numbers: not statistically different from zero, invalid parameter. * Maximum dose used in the experiments.